MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

Search

BioCryst Pharmaceuticals Inc

Suletud

SektorTervishoid

8.88 -1.99

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.85

Max

9.06

Põhinäitajad

By Trading Economics

Sissetulek

27M

32K

Müük

14M

146M

Kasumimarginaal

0.022

Töötajad

580

EBITDA

22M

21M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+80.02% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-18M

1.8B

Eelmine avamishind

10.87

Eelmine sulgemishind

8.88

Uudiste sentiment

By Acuity

85%

15%

354 / 376 Pingereas Healthcare

BioCryst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuli 2025, 15:46 UTC

Suurimad hinnamuutused turgudel

BitMine Shares Fall After Closing of $250 Million Private Placement

9. juuli 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9. juuli 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. juuli 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9. juuli 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9. juuli 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9. juuli 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuli 2025, 20:26 UTC

Tulu

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9. juuli 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9. juuli 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9. juuli 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9. juuli 2025, 17:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9. juuli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9. juuli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. juuli 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. juuli 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9. juuli 2025, 16:14 UTC

Omandamised, ülevõtmised, äriostud

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9. juuli 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9. juuli 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9. juuli 2025, 15:31 UTC

Suurimad hinnamuutused turgudel

BitMine Shares Fall After Closing of $250M Private Placement

9. juuli 2025, 15:31 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9. juuli 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9. juuli 2025, 14:36 UTC

Omandamised, ülevõtmised, äriostud

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9. juuli 2025, 14:31 UTC

Omandamised, ülevõtmised, äriostud

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9. juuli 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9. juuli 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

80.02% tõus

12 kuu keskmine prognoos

Keskmine 16.31 USD  80.02%

Kõrge 30 USD

Madal 11 USD

Põhineb 13 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

11

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

354 / 376 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.